|
시장보고서
상품코드
2075953
정신분열증 치료제 시장 : 치료법별, 투여 경로별, 환자 속성별, 지역별Schizophrenia Therapeutic Market, By Therapy Type, By Administration Route, By Patient Demographics, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
정신분열증 치료제 시장은 2026년에 78억 달러로 추정되며, 2033년까지 124억 달러에 이를 전망입니다. 2026-2033년 CAGR 8.3%를 나타낼 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 78억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 8.30% | 시장 규모 예측(2033년) : | 124억 달러 |
세계의 정신분열증 치료제 시장은 비정형 항정신병제, 정형 항정신병제, 보조 요법 등의 치료법별 범주로 구성되어 있으며, 경구용 정제, 지속형 주사제(LAI), 경피 흡수제 등의 제형이 제공되고 있습니다. 이러한 제품들은 성인, 청소년, 고령자 등 다양한 분야에서 채택되어 효율성, 성능 및 신뢰성 향상에 기여하고 있습니다. 이러한 부문에서의 채용 확대와 지속적인 제품 혁신이 맞물려 시장 확대를 지속적으로 뒷받침하고 있습니다.
시장 역학 :
주요 적용 분야 수요 증가, 효율성과 성능에 대한 중요성 부각, 그리고 지속적인 제품 혁신이 전 세계 정신분열증 치료제 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 성인 및 청년층을 대상으로 한 채용 확대와 첨단 솔루션에 대한 투자 증가가 시장 성장을 더욱 뒷받침하고 있습니다.
예를 들어, 각 기업은 경구용 정제 및 관련 용도에 특화된 제품 개발을 점점 더 적극적으로 추진하고 있습니다. 또한, 지속적인 연구 개발과 신기술의 통합을 통해 예측 기간 동안 시장 참여자들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 세계 정신분열증 치료제 시장의 주요 기업 프로파일을 소개했습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 책 '세계의 정신분열증 치료제 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 정신분열증 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 개요
제3장 시장 역학, 규제 및 동향 분석
제4장 정신분열증 치료 시장 : 요법 유형별(2026-2033년)
제5장 정신분열증 치료 시장 : 투여 경로별(2026-2033년)
제6장 정신분열증 치료 시장 : 환자 속성별(2026-2033년)
제7장 정신분열증 치료 시장 : 지역별(2026-2033년)
제1장 경쟁 구도
제2장 섹션
AJY 26.07.09Schizophrenia Therapeutic Market is estimated to be valued at USD 7.80 billion in 2026 and is expected to reach USD 12.4 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.80 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.30% | 2033 Value Projection: | USD 12.4 billion |
The global schizophrenia therapeutic market comprises therapy type categories such as Atypical Antipsychotics, Typical Antipsychotics, and Adjunctive Therapies, serving applications including Oral Tablets, Long-Acting Injectables(LAIs), and Transdermal. These offerings are adopted across Adult, Adolescent, and Geriatric and other areas, where they support improved efficiency, performance, and reliability. Growing adoption across these segments, combined with ongoing product innovation, continues to support expansion of the market.
Market Dynamics:
Rising demand across key application areas, increasing emphasis on efficiency and performance, and continued product innovation are major factors expected to drive growth of the global schizophrenia therapeutic market. Expanding adoption among Adult, and Adolescent and growing investment in advanced solutions are further supporting market expansion.
For instance, providers are increasingly developing offerings tailored to Oral Tablets and related applications. Moreover, ongoing research and development, along with the integration of new technologies, is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global schizophrenia therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., Johnson & Johnson, Otsuka Pharmaceutical Co, Ltd., Novartis AG, Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, Recordati S.p.A., Mylan N.V., Alkermes plc, Takeda Pharmaceutical Company Limited, and Acadia Pharmaceuticals Inc, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global schizophrenia therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global schizophrenia therapeutic market.
Detailed Segmentation:
- Global Schizophrenia Therapeutic Market, By Therapy Type (Revenue, USD Bn, 2021 - 2033)
- Atypical Antipsychotics
- Typical Antipsychotics
- Adjunctive Therapies
- Psychosocial Interventions
- Others
- Global Schizophrenia Therapeutic Market, By Administration Route (Revenue, USD Bn, 2021 - 2033)
- Oral Tablets
- Long-Acting Injectables(LAIs)
- Transdermal
- Others
- Global Schizophrenia Therapeutic Market, By Patient Demographics (Revenue, USD Bn, 2021 - 2033)
- Adult
- Adolescent
- Geriatric
- andOthers
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Pfizer Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Johnson & Johnson
- Otsuka Pharmaceutical Co, Ltd.
- Novartis AG
- Sunovion Pharmaceuticals Inc.
- H. Lundbeck A/S
- Recordati S.p.A.
- Mylan N.V.
- Alkermes plc
- Takeda Pharmaceutical Company Limited
- Acadia Pharmaceuticals Inc
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Administration Route
- Market Snapshot, By Patient Demographics
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Schizophrenia Therapeutic Market By Therapy Type, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Atypical Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Typical Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Adjunctive Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Psychosocial Interventions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Schizophrenia Therapeutic Market By Administration Route, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Long-Acting Injectables (LAIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Schizophrenia Therapeutic Market By Patient Demographics, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Adolescent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Schizophrenia Therapeutic Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, en2026-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Administration Route, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Demographics, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Administration Route, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Demographics, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Administration Route, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Demographics, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Administration Route, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Demographics, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Administration Route, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Demographics, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sunovion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- H. Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Recordati S.p.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alkermes plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Company Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Acadia Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
